In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Aquestive Therapeutics Inc (NASDAQ: AQST) closed at $3.10 in the last session, up 1.97% from day before closing price of $3.04. In other words, the price has increased by $1.97 from its previous closing price. On the day, 1.68 million shares were traded. AQST stock price reached its highest trading level at $3.145 during the session, while it also had its lowest trading level at $2.92.
Ratios:
We take a closer look at AQST’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.85 and its Current Ratio is at 6.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on May 10, 2024, initiated with a Outperform rating and assigned the stock a target price of $8.
On April 11, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $10.
On March 28, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $7.Raymond James initiated its Outperform rating on March 28, 2024, with a $7 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 15 ’24 when Schobel Alexander Mark sold 50,000 shares for $6.00 per share. The transaction valued at 300,000 led to the insider holds 984,476 shares of the business.
Schobel Alexander Mark sold 25,000 shares of AQST for $129,685 on Mar 08 ’24. The Chief Innovation/Tech Officer now owns 1,040,371 shares after completing the transaction at $5.19 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AQST now has a Market Capitalization of 282219328 and an Enterprise Value of 221499456. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.48. Its current Enterprise Value per Revenue stands at 4.301 whereas that against EBITDA is -12.17.
Stock Price History:
The Beta on a monthly basis for AQST is 2.80, which has changed by 0.9375 over the last 52 weeks, in comparison to a change of 0.23228896 over the same period for the S&P500. Over the past 52 weeks, AQST has reached a high of $6.23, while it has fallen to a 52-week low of $1.25. The 50-Day Moving Average of the stock is 8.43%, while the 200-Day Moving Average is calculated to be 11.49%.
Shares Statistics:
According to the various share statistics, AQST traded on average about 1.81M shares per day over the past 3-months and 1284824 shares per day over the past 10 days. A total of 91.04M shares are outstanding, with a floating share count of 79.75M. Insiders hold about 12.40% of the company’s shares, while institutions hold 39.46% stake in the company. Shares short for AQST as of 1719532800 were 7633267 with a Short Ratio of 4.22, compared to 1717113600 on 6700819. Therefore, it implies a Short% of Shares Outstanding of 7633267 and a Short% of Float of 10.040000000000001.
